Clinical trials: Adjuvant Treatment
Covid 19
Allogenic UCMSCs as Adjuvant Therapy for Severe COVID-19 Patients
This study is conducted to assess the efficacy and safety of stem cells as adjunctive treatment for severe COVID-19 patients. Here, we want to study whether the administration of mesenchymal stem cells are safe and able to…
- Trial name
- UCMSC (NCT05132972)
- Testing
- Normoxic Allogenic UCMSC, Normal saline solution
- Where
- 3 sites in Indonesia
- Volunteers
- 42 people
- Sponsor
- Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia
Bipolar Disorder, Depressive Disorder
Acute Effectiveness of Additional Drugs to the Standard Treatment of Depression
This study will compare the effectiveness of relatively new antidepressants which have different mechanisms of action. Buproprion (Wellbutrin) works on dopamine and the dopaminergic pathway.
- Trial name
- NCT00001483
- Testing
- buproprion (Wellbutrin), sertraline (Zoloft), venlafaxine (Effexor)
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Institute of Mental Health (NIMH)
is to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients.
Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace)
Aromatase inhibitors have shown a superior efficacy compared to tamoxifen in the treatment of hormonal receptor positive breast cancer in postmenopausal patients.
- Trial name
- PreFace (NCT01908556)
- Testing
- Letrozole
- Where
- Germany
- Volunteers
- 3,545 people
- Sponsor
- Institut fuer Frauengesundheit
Renal Cell Carcinoma
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
The primary objective of the study is to compare intismeran autogene plus pembrolizumab to placebo plus pembrolizumab in participants with renal cell carcinoma (RCC) with respect to disease-free survival (DFS) as assessed by the…
- Trial name
- INTerpath-004 (NCT06307431)
- Testing
- Intismeran autogene, Pembrolizumab
- Where
- 63 sites in United States, Argentina and 12 more
- Volunteers
- 272 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial
This study is a prospective, randomized, open-label, non-inferiority Phase III clinical trial, planning to enroll 2,934 patients, with a 1:1 allocation to either the conventional endocrine therapy group or the de-escalation…
- Trial name
- DESCENT (NCT07153757)
- Testing
- Endocrine Therapy of Physician's Choice
- Where
- China
- Volunteers
- 2,934 people
- Sponsor
- Fudan University
Diffuse Large B-cell Lymphoma
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients had achieved complete response with first-line rituximab-chemotherapy
- Trial name
- PILLAR2 (NCT00790036)
- Testing
- Everolimus
- Where
- 202 sites in United States, Argentina and 32 more
- Volunteers
- 742 people
- Sponsor
- Novartis Pharmaceuticals
Esophageal Cancer
Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma
This study was a multicenter, randomized, phase 3 trial to determine whether adjuvant chemotherapy including tisleliizumab improves recurrence-free survival compared to follow-up alone without chemotherapy in patients with…
- Trial name
- MRD2START (NCT06914011)
- Testing
- Tislelizumab
- Volunteers
- 172 people
- Sponsor
- Asan Medical Center
Colo-rectal Cancer, RAS Wild-type
Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model
In this exploratory phase II trial, the possibility of a personalized treatment after resistance to cetuximab will be evaluated.
- Conditions
- Colo-rectal Cancer, RAS Wild-type, UICC III, UICC II + RF
- Trial name
- 2016-003295-46 (NCT03263663)
- Testing
- targeted substance according to the avatar model
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- PD Dr. med. Volker Heinemann
Maximum Interincisal Opening
Effects of Exercise Therapy Adjuvant Device on Head and Neck Cancer Patients in the Treatment of Cancer Therapy Induced Trismus
Trismus is traditionally considered being a late effect of cancer therapy with functional deficits becoming clear in the first year after completing radiation therapy.
- Trial name
- NCT04740216
- Testing
- exercise therapy plus jaw device, exercise therapy
- Volunteers
- 130 people
- Sponsor
- Taipei Medical University
Breast Neoplasm, Hormone Receptor Positive Breast Carcinoma
Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer
This is a phase 2 single-arm, open-label determining efficacy of Neo-adjuvant Abemaciclib and Fulvestrant in subjects with Hormone receptor positive patients with localized non-metastatic breast cancer who develop local…
- Trial name
- NCT04305236
- Testing
- Abemaciclib, Fulvestrant
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of California, Irvine
Symptom Distress During Breast Cancer Treatment
Trajectory Analysis of Symptom Distress and Cancer-related Fatigue After Adjuvant Chemotherapy in Breast Cancer Female
When receiving adjuvant chemotherapy, a variety of symptoms will appear and it is very painful. These symptoms occur at the same time and are related to each other.
- Trial name
- NCT04911699
- Testing
- breast adenocarcinoma receiving chemotherapy, Control-for
- Volunteers
- 120 people
- Sponsor
- Taipei Medical University
MGMT-Unmethylated Glioblastoma
Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.
This is a prospective, open-label single-arm, exploratory, two-stage design trial, aiming to investigate safety and efficacy of AK105 with anlotinib and radiotherapy adjuvant therapy in MGMT unmethylated newly diagnosed…
- Trial name
- NCT05033587
- Testing
- Anlotinib, AK105, Radiotherapy
- Where
- China
- Volunteers
- 28 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Breast Neoplasms
To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent
To determine the Objective Response Rate of 4 cycles of docetaxel + anthracycline (epirubicin or doxorubicine) followed by 4 cycles of docetaxel single agent.
- Trial name
- NCT00620100
- Testing
- Docetaxel
- Where
- 2 sites in Austria, Poland
- Volunteers
- 2 people
- Sponsor
- Sanofi
Uterine Cervical Neoplasms, Chemoradiotherapy
Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer
This study carried out a prospective, randomized, controlled clinical study under the background of intensity-modulated radiation therapy and three-dimensional afterloading therapy.
- Conditions
- Uterine Cervical Neoplasms, Chemoradiotherapy, Adjuvant Chemotherapy
- Trial name
- NCT05735145
- Testing
- paclitaxel combined with platinum
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Fourth Affiliated Hospital of Guangxi Medical University
Hormone Therapy-induced Arthralgia, Phytotherapy
Evaluation of the Efficacy and Acceptability of a Phytotherapy Combining Devil's Claw, Blackcurrant and Meadowsweet for the Management of Aromatase Inhibitor-induced Arthralgia in Patients Treated for Localized Breast Cancer in the Adjuvant Setting
Adjuvant hormonotherapy is a cornerstone of treatment for localized hormone receptor-positive (HR+) breast cancer, accounting for approximately 80% of patients.
- Conditions
- Hormone Therapy-induced Arthralgia, Phytotherapy, Symptom Management, Adjuvant Treatment
- Trial name
- ERABLE (NCT07859319)
- Testing
- Phytotherapy Dietary Supplement (Harpagophytum, Meadowsweet, and Blackcurrant), Patient Experience Questionnaire
- Where
- 3 sites in France
- Volunteers
- 105 people
- Sponsor
- Hospices Civils de Lyon
Carcinoma, Esophagus Cancer
Tumor Antigen-sensitized DC Vaccine As an Adjuvant Therapy for Esophagus Cancer
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of tumor antigen-sensitized DC vaccine in postoperative adjuvant treatment of esophageal cancer.
- Trial name
- NCT05023928
- Testing
- Tumor antigen-sensitized DC vaccine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Sichuan University
Glioblastoma Multiforme
AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme
Phase 1b of the study, will evaluate the safety and tolerability of AQ4N treatment at three different dose levels. Phase 2a of the study, will further evaluate the safety, tolerability, and in addition efficacy of AQ4N treatment…
- Trial name
- NCT00394628
- Testing
- AQ4N, Temozolomide, Radiotherapy
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Novacea
Triple Negative Breast Cancer
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
The GLORIA study is a Phase III, randomized, open-label study to prospectively evaluate the efficacy and safety of adagloxad simolenin (OBI 822)/OBI-821 in the adjuvant treatment of patients with high risk, early stage Globo-H…
- Trial name
- NCT03562637
- Testing
- adagloxad simolenin combined with OBI-821, Globo H IHC Assay, Standard of care treatment
- Where
- 128 sites in United States, Australia and 11 more
- Volunteers
- 575 people
- Sponsor
- OBI Pharma, Inc
Breast Cancer, Early Breast Cancer
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease…
- Trial name
- CAMBRIA-2 (NCT05952557)
- Testing
- Camizestrant, Tamoxifen, Anastrozole
- Where
- 661 sites in United States, Argentina and 42 more
- Volunteers
- 5,511 people
- Sponsor
- AstraZeneca
Breast Cancer
Brass Mesh Bolus in Rotational Post-Mastectomy Radiation Therapy
The hypothesis is that the daily use of brass mesh bolus achieves a comparable dose to every-other-day use of Superflab bolus (current standard of care) in chest wall post-mastectomy patients treated with rotational 6 MV photon…
- Trial name
- NCT05483712
- Testing
- Brass Mesh Bolus
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Nova Scotia Cancer Centre
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.